Evaxion announces 89% vaccine target precision and sustained T-cell and clinical responses at three-year follow-up in phase 2 trial with personalized cancer vaccine EVX-01
Evaxion announced three-year data for its personalized cancer vaccine EVX-01 in advanced melanoma, showing an immune response in all patients and 89% of vaccine neoantigens inducing tumor-specific T-cell responses. All patients maintained their two-year clinical response with no tumor progression through the third year of EVX-01 monotherapy, supplementing prior two-year data of a 75% objective response rate and 25% complete response rate. The data will be presented at ESMO 2026 on October 24, followed by a KOL webinar on October 29.
Key figures
- Drug Name
- EVX-01
- Phase Of Trial
- Phase 2
- Cash runway
- well into the second half of 2027
- Patients enrolled
- 16
- Responders in extension
- 6 of 12
- Complete response rate 2yr
- 25%
- Patients responding at 2yr
- 92%
- Neoantigen target precision
- 89%
- Objective response rate 2yr
- 75%
- Target lesion tumor reduction
- 15 of 16 patients
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.